CCO Infectious Disease Podcast

Key Decisions in HIV Care: Switching to Long-Acting ART

Episode Summary

Listen as Daniel R. Kuritzkes, MD, explains key clinical trial data and gives practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure.

Episode Notes

In this episode, Daniel J. Kuritzkes, MD, reviews key clinical trial data and gives practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure. The overview will include analyses of:

• ATLAS and FLAIR studies of long-acting injectable CAB + RPV
• ATLAS 2M dosing study
• FDA approval and DHHS statement on use of long-acting injectable ART
• Studies on whether an oral lead-in is needed

Presenter:

Daniel R. Kuritzkes, MD
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Follow along with the slides at:
https://bit.ly/3hNfHII

See the entire program at:
https://bit.ly/2TXTYWx